BMS/Pfizer Eliquis under FDA review to prevent post-surgery DVT
This article was originally published in Scrip
Executive Summary
The FDA has accepted for review the supplemental new drug application (sNDA) for Pfizer's and Bristol-Myers Squibb's Eliquis (apixaban) to prevent deep vein thrombosis (DVT) – a blood clot in a vein, usually in the leg, that partially or totally blocks the flow of blood, which may lead to pulmonary embolism (PE) – in adults who have had hip or knee replacement surgery.